ClinicalTrials.gg
CompletedNCT04315558RARICOUpdated Oct 14, 2026Results posted

Revefenacin in Acute Respiratory Insufficiency in COPD

A Phase 2 interventional study of Revefenacin Inhalation Solution [Yupelri] and Ipratropium Bromide in COPD and Acute Respiratory Failure, sponsored by University of California, Los Angeles. Completed at 2 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of California, Los Angeles · Phase 2, Interventional, and Treatment

How we know

Updated Oct 14, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. revefenacin · Pulmonary Disease, Chronic Obstructive.

Enrollment
15th of 17
21 · median 122
Started
2020
with 1 other
Phase 2
5 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
1 of 17
University of California, Los Angeles

Among the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 2, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About revefenacin

revefenacin: first FDA approval 2018 (YUPELRI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

Read the detailed description

Objective: To assess the efficacy of nebulized revefenacin in improving the lung mechanics of COPD patients with acute respiratory failure requiring invasive mechanical ventilation (MV), in comparison to a control group receiving the short-acting muscarinic antagonist ipratropium.

Hypothesis: Revefenacin is as efficacious as ipratropium in improving the lung mechanics of COPD patients with acute respiratory failure.

Study Design:

RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

03

Conditions studied

  • COPD
  • Acute Respiratory Failure

Keywords

  • COPD
  • Acute Respiratory failure
  • Long acting muscarinic antagonist
  • nebulizer
  • mechanical ventilation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 40 years of age
  • Acute respiratory failure requiring invasive mechanical ventilation
  • Documented history of based on spirometric evidence of /FVC\<70%
  • Smoking history >10 years (current or prior)
  • Invasive mechanical ventilation for \< 96 hours

Exclusion criteria

Exclusion Criteria:

  • Chronic invasive mechanical ventilation via tracheostomy. Patients with tracheostomy alone without chronic mechanical ventilation may be enrolled.
  • Expected duration of mechanical ventilation \<24 hours
  • to muscarinic antagonists
  • Inability to tolerate albuterol
  • Lack of documented history
  • For patients taking short- or long-acting muscarinic antagonists (SAMAs or LAMAs) at the time of screening, inability or unwillingness to undergo the SAMA or LAMA (6 hours or 24 hours, respectively) prior to initiating study drug.
  • Presence of ARDS or acute congestive heart failure
  • Unwillingness or inability to remain on the study drug with for the duration of the study
  • Unwillingness or inability to have open-label muscarinic antagonists withheld for duration of the study
  • Unwillingness or inability to utilize the Puritan-Bennett 980 (PB980) ventilator
  • Pulmonary comorbidities such as pneumothorax or pneumomediastinum that, in the opinion of the investigator or clinical team, can pose a risk to subject safety or interfere with the subject's ability to complete the study procedures.
  • Documented restrictive lung disease or history of interstitial lung disease
  • Actual body weight exceeding 1 kg per centimeter of height
  • Pregnancy
  • or ALT > 3 times the , or other acute or chronic liver disease
  • Known history of glaucoma
  • Enrollment in other interventional clinical trial
  • Moribund patient not expected to survive >24 hours
  • Decision to withhold life-sustaining treatment, except in those patients committed to full support except cardiopulmonary resuscitation
  • Inability to obtain from patient or legally authorized representative (LAR)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Revefenacin

    Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.

    Drug: Revefenacin Inhalation Solution [Yupelri]

  • Active comparator
    Ipratropium

    Nebulized ipratropium will be delivered via nebulizer Q6 hours.

    Drug: Ipratropium Bromide

Interventions

06

What researchers measure

Primary outcomes

  1. Respiratory Therapist Time Spent at the Bedside (Minutes Per Day)

    Respiratory therapist time spent delivering either Revefenacin or Ipratropium at the bedside (minutes per day)

    Time frame: 7 days

Secondary outcomes

  1. Safety of Revefenacin: Paradoxical Bronchospasm, Hypersensitivity Reaction, Severe Urinary Retention Not Explained by Other Reasons, Severe Constipation Not Explained by Other Reasons

    Number of participants who experienced adverse events not explained by other reasons

    Time frame: 7 days

  2. Reduction in Total Inspiratory Resistance Rdyn at the Time of Drug Trough

    Time frame: From the peak to trough within 24 hours

  3. Ventilator Days to Day 28

    Time spent on ventilator from the day of enrollment in the study through Day 28

    Time frame: 28 days post enrollment

Other outcomes

  1. Survival to Day 28

    alive at Day 28

    Time frame: 28 days

07

Results

Posted Oct 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneRevefenacinIpratropium
Started129
Completed129
Not completed00

Outcome measures

PrimaryRespiratory Therapist Time Spent at the Bedside (Minutes Per Day)

Respiratory therapist time spent delivering either Revefenacin or Ipratropium at the bedside (minutes per day)

Time frame:
7 days
Reported as:
Mean · minutes per day
Respiratory Therapist Time Spent at the Bedside (Minutes Per Day)
minutes per dayRevefenacin ArmIpratropium Arm
Respiratory Therapist Time Spent at the Bedside (Minutes Per Day)7.2 ± 1.026.8 ± 5.3
Statistical analysis
  • Revefenacin Arm vs Ipratropium Arm · Wilcoxon (Mann-Whitney) · p = 0.001 · Mean difference (final values): 19.6
SecondarySafety of Revefenacin: Paradoxical Bronchospasm, Hypersensitivity Reaction, Severe Urinary Retention Not Explained by Other Reasons, Severe Constipation Not Explained by Other Reasons

Number of participants who experienced adverse events not explained by other reasons

Time frame:
7 days
Reported as:
Number · events
Safety of Revefenacin: Paradoxical Bronchospasm, Hypersensitivity Reaction, Severe Urinary Retention Not Explained by Other Reasons, Severe Constipation Not Explained by Other Reasons
eventsRevefenacinIpratropium
Paradoxical bronchospasms00
Hypersensitivity reaction00
New Cardiac arrhythmia01
Severe urinary retention10
Severe constipation00
SecondaryReduction in Total Inspiratory Resistance Rdyn at the Time of Drug Trough
Time frame:
From the peak to trough within 24 hours
Reported as:
Mean · cmH2O/L/s
Reduction in Total Inspiratory Resistance Rdyn at the Time of Drug Trough
cmH2O/L/sRevefenacinIpratropium
Reduction in Total Inspiratory Resistance Rdyn at the Time of Drug Trough-0.9 ± 2.42.6 ± 3.3
SecondaryVentilator Days to Day 28

Time spent on ventilator from the day of enrollment in the study through Day 28

Time frame:
28 days post enrollment
Reported as:
Mean · day
Ventilator Days to Day 28
dayRevefenacinIpratropium
Ventilator Days to Day 2811.2 ± 10.512.2 ± 9.8
Statistical analysis
  • Revefenacin vs Ipratropium · Wilcoxon (Mann-Whitney) · p = 0.61
Other pre-specifiedSurvival to Day 28

alive at Day 28

Time frame:
28 days
Reported as:
Count of participants · Participants
Survival to Day 28
ParticipantsRevefenacinIpratropium
Survival to Day 28125
Statistical analysis
  • Revefenacin vs Ipratropium · Wilcoxon (Mann-Whitney) · p = 0.01

Adverse events

Collected over Hospital stay length, up to 60 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Revefenacin2/12 (16.7%)0/12 (0%)2/12 (16.7%)
Ipratropium4/9 (44.4%)0/9 (0%)1/9 (11.1%)
Most frequent other events
Most frequent other events
EventRevefenacinIpratropium
arrhythmiaCardiac disorders0/121/9
Urinary retentionRenal and urinary disorders1/120/9
transaminitisHepatobiliary disorders1/120/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RevefenacinIpratropiumTotal
<=18 years000
Between 18 and 65 years011
>=65 years12820
Age, Continuous
Age, Continuous(years)RevefenacinIpratropiumTotal
Mean77 ± 775 ± 1676 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)RevefenacinIpratropiumTotal
Female6410
Male6511
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RevefenacinIpratropiumTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander112
Black or African American246
White9312
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)RevefenacinIpratropiumTotal
United States12921
08

Study locations

2 sites
  • Ronald Reagan Medical Center at UCLA
    Los Angeles, California 90095, United States
  • Santa Monica UCLA
    Santa Monica, California 90404, United States
09

References and documents

Publications

  • Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019 Jul;153:38-43. doi: 10.1016/j.rmed.2019.05.010. Epub 2019 May 23. PubMed 31150963 ↗
  • Ferguson GT, Feldman G, Pudi KK, Barnes CN, Moran EJ, Haumann B, Pendyala S, Crater G. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):154-165. doi: 10.15326/jcopdf.6.2.2018.0152. Epub 2019 Apr 9. PubMed 30974049 ↗
  • Donohue JF, Feldman G, Sethi S, Barnes CN, Pendyala S, Bourdet D, Crater G. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulm Pharmacol Ther. 2019 Aug;57:101808. doi: 10.1016/j.pupt.2019.101808. Epub 2019 May 30. PubMed 31152911 ↗
  • Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018 Feb;48:71-79. doi: 10.1016/j.pupt.2017.10.003. Epub 2017 Oct 4. PubMed 28987804 ↗
  • Zielinski J. Effects of ipratropium bromide on pulmonary hemodynamics in COPD. Chest. 1995 Oct;108(4):1181-2. doi: 10.1378/chest.108.4.1181-b. No abstract available. PubMed 7555146 ↗
  • Rezaie N, Shams-Hosseini NS, Kashanizadeh A, Karimi MA. Ipratropium bromide is more effective than Salmeterol - Fluticason combination on O2 saturation patients with COPD. J Res Med Sci. 2013 Aug;18(8):731. No abstract available. PubMed 24379853 ↗
  • Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010 Jan;137(1):13-9. doi: 10.1378/chest.08-2367. Epub 2009 Apr 10. PubMed 19363211 ↗
  • Khan SY, O'Driscoll BR. Is nebulized saline a placebo in COPD? BMC Pulm Med. 2004 Sep 30;4:9. doi: 10.1186/1471-2466-4-9. PubMed 15458566 ↗
  • Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44. doi: 10.1164/rccm.2107138. PubMed 12421743 ↗
  • Breen D, Churches T, Hawker F, Torzillo PJ. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax. 2002 Jan;57(1):29-33. doi: 10.1136/thorax.57.1.29. PubMed 11809986 ↗
  • Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8. doi: 10.1056/NEJM200005043421801. PubMed 10793162 ↗
  • Maqsood MH, Rubab K, Maqsood MA. The Role of Revefenacin in Chronic Obstructive Pulmonary Disease. Cureus. 2019 Apr 10;11(4):e4428. doi: 10.7759/cureus.4428. PubMed 31245215 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2025, 50 months.

Results were first posted in Oct 2026, 1 year 9 months after primary completion.

Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 50 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 19, 2020
StartActual
Nov 1, 2020
Primary completionActual
Jan 1, 2025
CompletionActual
Jan 1, 2025
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Reduction in total inspiratory resistance Rstat at the time of drug troughNow Respiratory Therapist Time Spent at the Bedside (Minutes Per Day)Time frame: 7 days
Oct 14, 2026
Secondary outcomes
2 edited, 2 added, 7 removed
What changed in the outcomes
  • EditedReduction in total inspiratory resistanceTotal Inspiratory Resistance Rdyn at the timeTime of drug troughDrug TroughTime frame: 7 days → From the peak to trough within 24 hours
  • EditedVentilator-free days Days to dayDay 28Time frame: Hospital stay, expected to be less than 28 days → 28 days post enrollment
  • AddedSafety of Revefenacin: Paradoxical Bronchospasm, Hypersensitivity Reaction, Severe Urinary Retention Not Explained by Other Reasons, Severe Constipation Not Explained by Other ReasonsTime frame: 7 days
  • RemovedReduction in Resistive pressure (Pres) at the time of drug troughTime frame: 7 days
  • RemovedReduction in total inspiratory resistance Rstat at the time of drug peakTime frame: 7 days
  • RemovedPaCO2Time frame: 7 days
  • RemovedRespiratory therapist time at bedsideTime frame: 7 days
  • RemovedICU Length of stayTime frame: Hospital stay, expected to be less than 28 days
  • Addedother outcomeSurvival to Day 28Time frame: 28 days
  • Removedother outcomeExploratory: Ventilator compliance analysis (ventilator dyssynchrony, pressure-volume curve analysis, expiratory flow curve analysis)Time frame: 7 days
  • Removedother outcomeSafety: Paradoxical bronchospasm, Hypersensitivity reaction, Severe urinary retention not explained by other reasons, Severe constipation not explained by other reasonsTime frame: 7 days
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Reduction in total inspiratory resistance Rstat at the time of drug troughNow Respiratory Therapist Time Spent at the Bedside (Minutes Per Day)Time frame: 7 days
    Secondary outcomes 2 edited, 2 added, 7 removed
    What changed in the outcomes
    • EditedReduction in total inspiratory resistanceTotal Inspiratory Resistance Rdyn at the timeTime of drug troughDrug TroughTime frame: 7 days → From the peak to trough within 24 hours
    • EditedVentilator-free days Days to dayDay 28Time frame: Hospital stay, expected to be less than 28 days → 28 days post enrollment
    • AddedSafety of Revefenacin: Paradoxical Bronchospasm, Hypersensitivity Reaction, Severe Urinary Retention Not Explained by Other Reasons, Severe Constipation Not Explained by Other ReasonsTime frame: 7 days
    • RemovedReduction in Resistive pressure (Pres) at the time of drug troughTime frame: 7 days
    • RemovedReduction in total inspiratory resistance Rstat at the time of drug peakTime frame: 7 days
    • RemovedPaCO2Time frame: 7 days
    • RemovedRespiratory therapist time at bedsideTime frame: 7 days
    • RemovedICU Length of stayTime frame: Hospital stay, expected to be less than 28 days
    • Addedother outcomeSurvival to Day 28Time frame: 28 days
    • Removedother outcomeExploratory: Ventilator compliance analysis (ventilator dyssynchrony, pressure-volume curve analysis, expiratory flow curve analysis)Time frame: 7 days
    • Removedother outcomeSafety: Paradoxical bronchospasm, Hypersensitivity reaction, Severe urinary retention not explained by other reasons, Severe constipation not explained by other reasonsTime frame: 7 days
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04315558
Responsible party
Igor Barjaktarevic, MD, PhD (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Mar 19, 2020
Start date
Nov 1, 2020
Primary completion
Jan 1, 2025
Completion
Jan 1, 2025
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Study contacts

Igor Z Barjaktarevic, MD, PhD
principal investigator · University of California, Los Angeles
Donald Tashkin, MD
study director · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Revefenacin

Start the discussion